2021-10-12| Special

Are Digital Therapeutics the Next Generation of Medical Products?

by Sahana Shankar
Share To
Technology has made huge strides in not only health monitoring and disease diagnosis but also active therapeutics. It is a fast-growing health sector that has seen investments grow by 40% year on year since 2013.

A wide range of products backed by evidence and peer-reviewed studies are now available to address cognitive disorders like ADHD, autoimmune diseases, insomnia, and psychiatric disorders like schizophrenia. As a result, there is value for consumers (improved outcomes), physicians (real-time monitoring of symptoms), and investors (large market size), which can drive digital therapeutics for more cost-effective solutions in the future.

At the Biofuture conference, a panel consisting of diverse voices based on the broad spectrum of products in the digital therapeutics space discussed the evolution of digital therapeutics, how they serve unmet clinical needs, how they can redefine therapy/medicine in the future, and how to build successful and sustainable business models for the next generation of products.

GO Prime with only $1.49 now

AstraZeneca Welcomes Neurofibromatosis And Asthma Treatment Approvals in Japan
Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial
Arsenal Biosciences Announced Another $70 million Collaboration, This Time With Genentech
Sciwind Biosciences And SynerK Join Forces To Develop siRNA Therapeutics
Acticor Enrolls First Patient in Phase 2/3 Stroke Treatment Study
Daiichi Sankyo Wins Approval For Cancer Treatment in Japan
Seagen Strikes Potential $650 million Deal with LAVA Therapeutics for Cancer Treatment
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!